Spurious cough syrup incidents dent India’s image as pharmacy of world: Pharmexcil DG

Hyderabad: On a day Union health minister Mansukh Mandaviya reiterated the Indian government’s ‘zero tolerance’ policy on spurious medicines by asking 18 companies to shut shop, Pharmexcil director general R Uday Bhaskar said though exports have not been impacted, the issue has dented India’s image as the pharmacy of the world.“...WHO and regulators of different countries are talking about it and issuing public alerts. Whenever we have interactions with regulators the first point they want to discuss is on these issues only,” Bhaskar said.This was though cough syrups accounted for just $15 million of India’s total pharma exports of $25.4 billion in 2022-23 and 52% of India’s pharma exports go to stringently regulated markets like Europe, where exports recorded 15.5% growth for the first time, and US. On India falling short of the $27 billion target, Bhaskar said though exports grew only 3.25% in FY23 to $25.4 billion, Pharmexcil was gunning for $28 billion exports in 2023-24 as the US market, which has 31% share of exports, has stablised, which is a positive sign.Despite global headwinds that led to negative growth in key markets such as Africa (-5%) and CIS (-8%) Indian pharma crossed the $25 billion mark for the first time and grew 10.5% in April 2023 alone, an optimistic Bhaskar said while addressing mediapersons on the ninth edition of Pharmexcil’s flagship International Pharma Exhibition to be held in Hyderabad from July 5 to 7. He said IPHEX 2023 is a special edition being organised on the occasion of India’s G20 presidency and will include a G20 focussed CEOs roundtable of delegates from over 120 countries.
Stay updated with the latest news on Times of India. Don't miss daily games like Crossword, Sudoku, Location Guesser and Mini Crossword.